| 20.09 14:43 | dpa-AFX: CHMP Recommends Marketing Authorization For Pfizer, BioNTech's Omicron KP.2-adapted COVID-19 Vaccine |
| 20.09 14:22 | dpa-AFX: *PFIZER AND BIONTECH RECEIVES POSITIVE CHMP OPINION FOR OMICRON KP.2-ADAPTED COVID-19 VACCINE |
| 20.09 14:22 | dpa-AFX: *PFIZER, BIONTECH OBTAIN POSITIVE CHMP OPINION FOR OMICRON KP.2-ADAPTED COVID-19 VACCINE IN EU |
| 17.09 13:44 | dpa-AFX: ANALYSE-FLASH: Jefferies belässt Pfizer auf 'Buy' - Ziel 35 Dollar |
| 17.09 13:44 | dpa-AFX: Jefferies belässt Pfizer auf 'Buy' - Ziel 35 Dollar |
| 16.09 22:15 | MÄRKTE USA/Uneinheitlich - Zurückhaltung vor Zinsentscheid |
| 16.09 18:09 | MÄRKTE USA/Anleger bleiben vor Zinsentscheid vorsichtig |
| 16.09 15:42 | MÄRKTE USA/Uneinheitlich - Zweifel an iPhone-Nachfrage belasten Apple |
| 14.09 15:47 | dpa-AFX: Pfizer : Phase 2 Study Of Ponsegromab In Cancer Cachexia Meets Primary Endpoint |
| 14.09 11:15 | dpa-AFX: Pfizer's BRAFTOVI + MEKTOVI Delivers Long-Term Benefits In BRAF V600E-Mutant NSCLC |
| 12.09 16:11 | MÄRKTE USA/Atempause nach Aufholjagd - Moderna stark unter Druck |
| 11.09 12:49 | dpa-AFX: *PFIZER TO SHOWCASE NEXT-GENERATION CANDIDATES ACROSS ONCOLOGY PORTFOLIO AT ESMO CONGRESS 2024 |
| 06.09 07:26 | dpa-AFX: Basilea Receives $25 Mln Milestone Payment Following Strong Cresemba Sales Performance In Europe |
| 03.09 07:20 | dpa-AFX: Pfizer, Valneva Report Further Positive Phase 2 Booster Results For Lyme Disease Vaccine Candidate |
| 03.09 07:04 | dpa-AFX: *VALNEVA AND PFIZER REPORT FURTHER POSITIVE PHASE 2 BOOSTER RESULTS FOR LYME DISEASE VACCINE CANDIDATE |
| 01.09 19:26 | dpa-AFX: Weekly Biotech Buzz: BMRN Cuts Jobs, FDA Approves New Mpox Vaccine, MRK Halts 2 Keytruda Studies |
| 27.08 13:05 | dpa-AFX: Pfizer Launches Digital Platform PfizerForAll |
| 27.08 12:50 | dpa-AFX: *PFIZER UNVEILS LAUNCH OF DIGITAL PLATFORM PFIZERFORALL |
| 25.08 05:57 | dpa-AFX: Weekly Biotech Buzz: AADI Trims R&D Jobs, JNJ Loosens Purse Strings, FDA Snubs REGN's Myeloma Drug |
| 23.08 11:20 | dpa-AFX: ANALYSE-FLASH: Berenberg belässt Pfizer auf 'Hold' - Ziel 27 Dollar |
|
|
